- Regulation
- Approvals
Novartis gets EC nod for Cosentyx drug in paediatric psoriasis
Novartis has secured approval from the European Commission (EC) for its Cosentyx (secukinumab) to treat moderate-to-severe plaque psoriasis in children and adolescents aged between six and 18 years
![Novartis has secured EC approval for Cosentyx drug in paediatric psoriasis. (Credit: Novartis AG)](http://oazel.kartpark.net/wp-content/uploads/2024/08/Novartis.jpg)